nitrates has been researched along with Cytokine Release Syndrome in 1 studies
Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.
Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Accordingly, this study investigated the influence of the novel JAK inhibitor ruxolitinib (RXB) on concanavalin A (Con A)-induced hepatitis and systemic hyperinflammation in mice to simulate the context occurring in COVID-19 patients." | 4.12 | The JAK inhibitor ruxolitinib abrogates immune hepatitis instigated by concanavalin A in mice. ( El-Mesery, M; Hazem, SH; Hendawy, OM; Shaker, ME, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shaker, ME | 1 |
| Hendawy, OM | 1 |
| El-Mesery, M | 1 |
| Hazem, SH | 1 |
1 other study available for nitrates and Cytokine Release Syndrome
| Article | Year |
|---|---|
The JAK inhibitor ruxolitinib abrogates immune hepatitis instigated by concanavalin A in mice.
Topics: Aldehydes; Animals; Chemical and Drug Induced Liver Injury; Concanavalin A; Cytokine Release Syndrom | 2022 |